The U.S. Food and Drug Administration has declined to approve a lung cancer drug U.S. drugmaker Eli Lilly and its Chinese partner tested clinically only in China.
Lilly said the U.S. Food and Drug Administration (FDA) recommended an additional multi-regional clinical trial for the drug known as sintilimab, according to a press release dated March 24.